Last updated 7 days ago
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
160 patients around the world
Available in Argentina, United States
argenx
1Research sites
160Patients around the world
This study is for people with
Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy - CIDP
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021).Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP.Has residual disability and active disease.Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors).Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP.
- Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021).Sensory CIDP (including sensory-predominant CIDP).Polyneuropathy of other causes.Clinical diagnosis of systemic lupus erythematosus (SLE).Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation.
Sites
INECO Neurociencias Oroño - Rosario
Studyemnergize
Sponsorargenx
Study typeInterventional
Conditions
Chronic inflammatory demyelinating polyneuropathy - CIDP
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07091630
